# PUBLIC SUMMARY DOCUMENT

**Product:** Omnigon Eakin Freeseal

**Applicant:** Omnigon

**Date of SPAP Meeting:** 20 April 2021

## Proposed Listing on the Stoma Appliance Scheme

The applicant, Omnigon sought listing of the Omnigon Eakin Freeseal in subgroup 9(l) of the Stoma Appliance Scheme (SAS) Schedule. The proposed product, including one variant, was proposed for listing at a unit price of $4.531, with a maximum monthly quantity of 30 units.

## Comparator

The applicant nominated the Omnigon Cohesive Seal (SAS code 9975B) as the comparator. The product is currently listed in subgroup 9(l) of the SAS Schedule at the unit price of $4.531, with a maximum monthly quantity of 30 units. The Stoma Product Assessment Panel (SPAP) accepted this product as an acceptable comparator

## Background

This was the SPAP’s first consideration of this product.

## Clinical Place for the Product

The proposed product is an alternative for users requiring a product to improve the seal around the stoma, protecting peristomal skin from corrosive output.

## SPAP Comment

### Clinical Analysis

The Panel noted that the proposed product claims to be thinner and less obstrusive than the comparator. The Panel also noted that the applicant states that comparisons with the comparator were undertaken for comfort level and also refers to a number of physical tests however, no data was provided.

The proposed product is considered to be equivalent to products currently available at the benchmark price in subgroup 9(l).

### Economic Analysis

Not undertaken.

### Financial Analysis

Listing of this product is recommended on a cost-minimisation basis compared to products currently listed in subgroup 9(l) of the SAS Schedule. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of listing this product.

## SPAP Recommendation

The SPAP recommended that the Omnigon Eakin Freeseal, including one variant be listed in subgroup 9(l) of the SAS Schedule at the unit price of $4.531, with a maximum monthly quantity of 30 units.

## Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. A SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

## Applicant’s Comment

Omnigon agrees with the SPAP’s recommendation.